WallStSmart
LRMR

Larimar Therapeutics Inc

NASDAQ: LRMR · HEALTHCARE · BIOTECHNOLOGY

$4.13
-3.65% today

Updated 2026-06-05

Market cap
$329.31M
P/E ratio
P/S ratio
EPS (TTM)
$-2.12
Dividend yield
52W range
$2 – $6
Volume
1.6M

Larimar Therapeutics Inc (LRMR) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-105.04%
ROA
-56.90%
Debt/equity
0.02x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2011$-13.16M
2012$-13.88M
2013$-14.03M
2014$-36.57M
2015$-74.29M
2016$-57.88M
2017$-52.03M
2018$-61.37M
2019$0.00$-23.13M
2020$0.00$-42.33M
2021$0.00$-50.31M
2022$0.00$-34.18M
2023$0.00$-36.95M
2024$0.00$-80.60M
2025$0.00$-165.67M

Frequently asked questions

How much free cash flow does LRMR generate?

LRMR produced $-113.29M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is LRMR's balance sheet healthy?

LRMR holds $85.41M in cash and equivalents against — in long-term debt, on $78.08M of shareholder equity. That debt is best read against the cash flow the business throws off each year.